GleanMark

CTX310 Trademark

CTX310 is a USPTO trademark filed by CRISPR Therapeutics AG. Status: Registered.

Trademark Facts

MarkCTX310
Serial Number97461217
Registration Number8005333
StatusRegistered
Filing Date2022-06-16
Registration Date2025-10-28
Mark TypeWord
Nice Classes005 (Pharmaceuticals), 042 (Software & IT)
OwnerCRISPR Therapeutics AG
Attorney of RecordTiffany D. Gehrke
Prosecution Events46
Latest EventNRCC on 2025-10-28

Goods & Services

Cells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of cardiovascular diseases; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular disease in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular disease in the field of in vivo gene editing therapy; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy

Related